immunotherapy

CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital

SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage…

2 days ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

[IMAGES BELOW] 11-month sustained complete resolution of lung metastasis observed in Bria-OTS Phase 1/2a metastatic breast cancer study.No treatment limiting…

2 days ago

Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates

Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences…

7 days ago

CytomX Therapeutics Announces Business Update and Company Milestones for 2026

- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”)…

7 days ago

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European…

7 days ago

BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer

Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or…

7 days ago

JOURNAL OF TRANSLATIONAL MEDICINE PUBLISHES PAPER HIGHLIGHTING POTENTIAL OF THE ELEPHAS LIVE™ PLATFORM TO TRANSFORM IMMUNOTHERAPY OUTCOMES

 Innovative Platform Aims to Boost Response Rates and Improve Lives of Cancer PatientsMADISON, Wis., Jan. 6, 2026 /PRNewswire/ -- Elephas…

1 week ago

NanOlogy Appoints John M. Goldberg, MD as Chief Medical Officer to Further its Preclinical & Clinical Large Surface Area Microparticle Investigational Drug Portfolio

FORT WORTH, Texas, Jan. 6, 2026 /PRNewswire/ -- NanOlogy, LLC, a clinical-stage oncology company, today announced the appointment of John…

1 week ago

Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared

~ Annual/Special Meeting of Shareholders to be Held on January 30, 2026 ~WEXFORD, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) --…

1 week ago